Large copy number variants in UK Biobank caused by clonal haematopoiesis may confound penetrance estimates by Tuke, M et al.
 1 
Large copy number variants in UK Biobank caused by clonal haematopoiesis may 
confound penetrance estimates 
 
Marcus Tuke1, Jessica Tyrrell1, Katherine S. Ruth1, Robin N. Beaumont1, Andrew R. Wood1, 
Anna Murray1, Timothy M. Frayling1, Michael N. Weedon1, Caroline F. Wright1* 
 
1 Institute of Biomedical and Clinical Science, University of Exeter Medical School, RILD 
Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter UK, EX2 5DW 
 




Large copy number variants (CNVs) are strongly associated with both developmental delay 
and cancer, but the type of disease depends strongly on when and where the mutation 
occurred, i.e. germline versus somatic. We used microarray data from UK Biobank to 
investigate the prevalence and penetrance of large autosomal CNVs and chromosomal 
aneuploidies using a standard CNV detection algorithm not designed for detecting mosaic 
variants. We found 160 individuals that carry >10Mb copy number changes, including 56 
with whole chromosome aneuploidies. Nineteen (12%) individuals had a diagnosis of 
Down’s syndrome or other developmental disorder, while 84 (52.5%) individuals had a 
diagnosis of haematological malignancies or chronic myeloproliferative disorders. Notably, 
there was no evidence of mosaicism in the blood for many of these large CNVs, so they 
could easily be mistaken for germline alleles even when caused by somatic mutations. We 
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therefore suggest that somatic mutations associated with blood cancers may result in false 





Copy number variants (CNVs) are deletions or duplications of DNA that can vary in size from 
50 basepairs to several hundred megabases1, i.e. entire chromosomes. Individuals typically 
carry several thousand CNVs, most of which are small (<1Mb) and rare (allele frequency 
<1%)2–4. Large, rare pathogenic CNVs have historically been identified through clinical 
microarray testing of two distinct clinical cohorts: firstly, children with developmental 
disorders caused predominantly by germline mutations5–7, and secondly, individuals with 
haematological and other cancers associated with somatically-acquired mutations8–10.  
 
The availability of large, well-genotyped population biobanks offers an opportunity to 
investigate the prevalence and penetrance of monogenic disease-causing variants11. Several 
studies have already been published evaluating known developmental CNVs in 500,000 
adults in the UK and Estonian Biobanks12–19 and the penetrance of X-chromosome 
aneuploidy has been investigated in UK Biobank20. However, given the relatively advanced 
age of UK Biobank participants, ranging from 40–70 years (mean = 56.5 years) at 
recruitment, it is likely that some variants will be due to somatic mutation and age-related 
clonal haematopoiesis21,22 as has previously been observed in genome-wide association 
study cohorts23,24. Importantly, somatic variants in adult population cohorts should not be 
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used to evaluate the penetrance of germline CNVs known to cause developmental 
disorders, as this will result in spurious associations. 
 
We sought to investigate large (>10Mb) autosomal CNVs present in population datasets 
with the aim of determining whether they were likely to be germline (and therefore 
potentially useful for penetrance studies) or somatic (and therefore caused by clonal 
expansions). We used microarray data from UK Biobank, which recruited 502,506 
individuals from across the UK between 2006-201025. Hospital Episode Statistics (HES) and 
cancer registry data were available for the whole cohort up to 31 March 2017, and GP 
records were available for half the cohort; all participants also provided a range of 
information (e.g., demographics, health status, lifestyle) via questionnaires. Genotypes for 
SNVs and indels were generated from blood-extracted DNA using the Affymetrix Axiom UK 
Biobank array (~450,000 individuals) and the UKBiLEVE array (~50,000 individuals) in 106 
batches of ~4,700 samples. This dataset underwent extensive central quality control25.  
 
We called CNVs genome-wide in 488,377 individuals with array genotyping data in UK 
Biobank25 using PennCNV version 1.0.426 with log R ratio and B-allele frequency values for 
805,426 genome-wide probe sets provided by UK Biobank. Very large PennCNV calls (i.e. 
multiple megabases) can sometimes be fragmented into many smaller calls, so we 
additionally calculated the sum of bases either deleted or duplicated on each chromosome 
per individual according to the PennCNV calls. We carried out visual inspection of each 
event in everyone with >10Mb deleted and/or duplicated on a single chromosome to 
confirm breakpoints, event type and level of mosaicism (see examples in Figure 1). Around a 
third of the events showed no evidence of mosaicism in blood (based on a deviation of the 
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B-allele frequencies from 0, 0.5 or 1 with a co-located increase/decrease in log R ratio) while 
two-thirds of events were consistent with the presence of a large CNV in a proportion of 
cells. Based on previous work investigating mosaicism in UK Biobank20,27, we estimate that 
we were able to detect copy number changes present in >20-25% of cells. There was a good 
correlation between the log R ratio and visual inspection of mosaicism28 (Figure 2). 
 
We identified 160 individuals in UK Biobank (61% male versus 46% in the whole of UK 
Biobank; Pearson’s Chi-squared p=0.025) with >10Mb involved in copy number events on a 
single autosome (Figure 3 and Supplementary Table 1). This male bias has been observed 
previously and is thought to be due to higher male-specific rates of certain haematological 
malignancies24. In the majority (134/160) of individuals, this was caused by a single large 
CNV; 19 individuals had two separate events (17 on two different chromosomes), five 
individuals had three separate events (all involving at least two different chromosomes) and 
two individuals had four or five separate events on the same chromosome. Individual events 
ranged in size from 0.9Mb-198Mb (mean=56Mb, stdev=51Mb), and included both unique 
events and recurrent events. There were 64 whole chromosome duplications of 
chromosomes 3, 8, 9, 12, 14, 18, 19 and 21, including four individuals with two trisomies 
and three individuals with three trisomies.  
 
Of the autosomal aneuploidies, only trisomy 21 is compatible with adult life when present 
constitutively and causes Down’s Syndrome 29. Twelve individuals had a duplication of 
chromosome 21, of whom 11 had a diagnosis of Down’s syndrome in their HES or GP 
records (GP records were not available for the remaining individual). A further six individuals 
in UK Biobank had Down’s syndrome recorded in their HES records, but their microarray 
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data showed no evidence of trisomy 21. It is unclear whether these discrepancies are 
caused by sample mix-ups, errors in HES records, or misdiagnoses. Of those with large CNVs, 
a further eight individuals had ICD-10 codes or GP records consistent with various 
developmental disorders, including congenital malformations, developmental disorder 
(intellectual disability/handicap or epilepsy) and bipolar affective disorder (Supplementary 
Table 1).  
 
We suggest that the rest of the whole chromosome duplications and the majority of large 
CNVs are likely to be somatic mutations caused by clonal expansions, some of which are 
compatible with being present in (apparently) healthy individuals. Several lines of evidence 
suggest that the majority of the large CNVs were likely caused by somatic mutations 
associated with either cancer10,30 or age-related haematopoietic clonal expansions22,31. First, 
79/160 (50%) individuals had a recurrent duplication of chromosome 8, 9, 12 or 19 or large 
deletions on chromosome 11q, 13q, 17p and 20q that are consistent with those observed 
previously in lymphocytic and myeloid leukaemias10,30,32,33 and JAK2-related 
myeloproliferative neoplasms34. Second, 98/160 (61%) individuals had neoplasms recorded 
in their HES records or cancer registry data compared with 80,046 (17%) across the whole of 
UK Biobank (p< 2x10-16). Sixty-four (40%) were malignant neoplasms of lymphoid, 
haematopoietic and related tissues (ICD-10 codes: C81-96), a significant enrichment above 
the whole of UK Biobank (n=3869, 0.8%, p< 2x10-16); and a further 20 were polycythemia 
vera, myelodysplastic syndrome and chronic myeloproliferative diseases (ICD-10 codes: 
D45-47), again a significant enrichment above the whole of UK Biobank (n=646, 0.1% p< 
2x10-16). Third, individuals with large CNVs and neoplasms were older and taller versus the 
others with large CNVs but no record of neoplasms, as expected in cancer; in contrast, 
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individuals with large CNVs and a developmental disorder were younger and shorter versus 
the others, as expected with most developmental disorders (Figure 4).  
 
Nonetheless, 43/160 (27%) individuals with a large CNV in UK Biobank have neither a 
developmental disorder nor a neoplasm (of any sort) recorded to date. This observation has 
a range of explanations, including record error, lack of hospitalisation, absence of GP 
records (currently only available for around half the cohort), benign haematopoietic clonal 
expansions, or neoplasms that have not yet developed or been diagnosed. Given the 
prognostic link between chromosomal instability and tumorigenesis30,35, unfortunately the 
latter explanation is likely to be true in many cases. 
 
Mosaic chromosomal alterations27 and Y chromosome loss36 in UK Biobank have previously 
been linked to age-related clonal haematopoiesis, both of which can be easily excluded 
from studies seeking to investigate penetrance of germline CNVs. Indeed, although some 
mosaic variants can be detected by PennCNV, low-level mosaic variants are often not 
detected using standard variant calling algorithms. However, the presence of very rare 
autosomal aneuploidies, some of which do not appear to be mosaic based on intensity data 
from microarrays, suggest that caution should be used when interpreting rare variants (of 
any size) in population biobanks. For example, we note that six individuals in UK Biobank 
have complete or partial trisomy of chromosome 3, of whom 5/6 have non-Hodgkin’s 
lymphoma. Presumed germline duplications of 3q29 have previously been causally linked 
with early death (OR=27.8) and cancer (OR=37.5) in UK Biobank12, but we suggest that these 
associations more likely reflect reverse causality, with cancer causing both the mutations 
and early death. A similar issue has previously been highlighted for sequence variants in 
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cancer driver genes where rare mutations are also a cause of developmental disorders, such 
as ASXL1 and DNMT3A37. Based on our analysis, the issue of somatic mutations confounding 
analyses of variants presumed to be germline can only be partially addressed by assigning 
the mosaic status of each variant; critically evaluating the validity of a variant (such as the 
breakpoints of a CNV), the plausibility of a finding (such as presence of constitutive 
autosomal aneuploidy) and likelihood of different mutational mechanisms (such as clonal 
expansion) are also important. As genome-wide sequencing becomes widely available in 
aging cohorts such as UK Biobank, researchers should be aware of potential confounding 
caused by somatic mutations present in high proportions of cells. 
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Figure 1. Example mean log R ratio (LRR) and B-allele frequency plots.  
(a) Constitutive deletion of half the q-arm of chromosome 20, (b) four small non-mosaic 
deletions on chromosome 4, (c) mosaic deletion of the end of the q-arm of chromosome 6, 
(d) constitutive duplication of the whole of chromosome 21, (e) mosaic duplication of the 
whole of chromosome 19 and (f) triplication of chromosome 9p. Alleles (A and B) 
corresponding to each of B-allele frequencies are indicated. Red = copy number change; 
blue = normal copy number. 
 
Figure 2. Mean log R ratio of CNVs 
Boxplot of mean log R ratios of large CNVs, grouped by whether there was evidence of 
mosaicism based on visual inspection of the data. Red = deletion (DEL); blue = duplication 
(DUP); green = triplication (TRIP).  
 
Figure 3. Summary of large autosomal CNVs identified  
Circos plot of all large autosomal CNVs in UK Biobank; chromosomes 1-22 are indicated, and 
CNVs on the same chromosome in the same person are shown on the same track. Red = 
deletion; blue = duplication; green = triplication.  
 
Figure 4. Characteristics of individuals in UK Biobank with >10MB copy number changes.  
(a) Age in years at recruitment and (b) height of individuals grouped by whether they had a 
neoplasm, developmental disorder or neither coded in their HES or cancer registry records. 
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Red = developmental disorder; green = neoplasm; blue = neither neoplasm nor 




Supplementary Table 1. List of all >10MB copy number changes in UK Biobank detected 
using SNP-genotyping arrays. DUP = duplication, DEL = deletion, LRR = log R ratio, St Dev LRR 
= standard deviation of the log R ratio, N SNPs = number of SNPs in the call. 
 
